An important example of the distinction between surrogate endpoints and clinical outcomes in drug development

The U.S. Food and Drug Administration (FDA) has approved Tryngolza (olezarsen), the first treatment shown to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia (SHTG).

Developed by Ionis Pharmaceuticals, Tryngolza is indicated for use in combination with diet to reduce triglyceride levels and lower the risk of acute pancreatitis in adults with fasting triglyceride levels of 500 mg/dL or greater.

The approval marks an important milestone for patients with severe hypertriglyceridemia, a condition associated with significantly elevated triglyceride levels and an increased risk of acute pancreatitis, a potentially serious and life-threatening inflammatory condition of the pancreas.

A Significant Unmet Medical Need

Clinical guidelines recommend lowering triglycerides when levels exceed 500 mg/dL to reduce pancreatitis risk. While several medications have previously been approved to reduce triglycerides, none had demonstrated a reduction in acute pancreatitis risk sufficient to support an FDA-approved claim.

Patients enrolled in the Tryngolza clinical trials had average baseline triglyceride levels exceeding 1,100 mg/dL, highlighting the severity of disease among study participants.

Clinical Trial Results

FDA’s approval was supported by two randomized, double-blind, placebo-controlled Phase 3 clinical trials involving 1,061 adults with severe hypertriglyceridemia.

The primary endpoint evaluated the percentage reduction in fasting triglyceride levels after six months of treatment.

Across the two studies:

Patients receiving the 50 mg dose experienced triglyceride reductions ranging from 49% to 63%.

Patients receiving the 80 mg dose experienced triglyceride reductions ranging from 55% to 72%.

An integrated analysis demonstrated a reduction in acute pancreatitis events among patients receiving Tryngolza compared to placebo.

The ability to demonstrate both substantial triglyceride reduction and a reduction in pancreatitis risk distinguishes Tryngolza from previously approved therapies in this treatment area.

Safety Profile

The most reported adverse reactions included injection site reactions and elevated liver enzymes.

FDA recommends consideration of liver function monitoring before initiating therapy and during treatment when clinically indicated.

Potential hypersensitivity reactions, including rash, hives, facial swelling, chills, and difficulty breathing, have also been reported. Patients experiencing signs of allergic reactions should discontinue treatment and seek medical attention.

Regulatory Significance

Tryngolza received both Breakthrough Therapy and Priority Review designations, reflecting FDA’s assessment that the therapy addressed a significant unmet medical need.

The approval also highlights the continued maturation of antisense oligonucleotide technologies, which target disease-causing genetic pathways through highly specific RNA-based mechanisms.

As precision medicine continues to evolve, approvals such as Tryngolza demonstrate the growing role of advanced molecular therapies in treating conditions that previously had limited therapeutic options.

MDP Perspective

The approval of Tryngolza for severe hypertriglyceridemia represents an important example of the distinction between surrogate endpoints and clinical outcomes in drug development.

Historically, therapies for severe hypertriglyceridemia have been approved because they lowered triglyceride levels, a surrogate marker associated with disease risk. While reductions in triglycerides are generally expected to improve patient outcomes, demonstrating a direct clinical benefit requires additional evidence.

What distinguishes this approval is FDA’s conclusion that clinical trial data demonstrated not only substantial reductions in triglyceride levels but also a reduction in acute pancreatitis risk, a clinically meaningful outcome for patients.

From a regulatory science perspective, this approval highlights FDA’s ongoing emphasis on connecting biomarker improvements to tangible patient benefits whenever possible.

The approval also demonstrates the value of well-designed clinical development programs capable of generating evidence that extends beyond laboratory measurements to show meaningful impacts on patient health.